# Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

> **NCT04640480** · PHASE1 · COMPLETED · sponsor: **SN BioScience** · enrollment: 21 (actual)

## Conditions studied

- Colorectal Cancer
- Breast Cancer
- Pancreas Cancer
- Ovarian Cancer
- Small-cell Lung Cancer
- Gastric Cancer
- Head and Neck Cancer

## Interventions

- **DRUG:** SNB-101

## Key facts

- **NCT ID:** NCT04640480
- **Lead sponsor:** SN BioScience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-21
- **Primary completion:** 2026-01-05
- **Final completion:** 2026-01-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640480, "Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04640480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*